| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Epstein-Barr Virus Early Antigen Ab, IgG
MessageSendout, Mayo test code: EBVE
Test Code
LAB654
Alias/See Also
EBV IgG Antibody to Early Antigen
E. B. Virus (Early Antigen)
EA (Early Antigen)
Early Antigen EBV EARLY AG(S)
Epstein Barr Virus Early Ag Ab
Epstein-Barr Virus (EBV) Early Antigen
EBVE
E. B. Virus (Early Antigen)
EA (Early Antigen)
Early Antigen EBV EARLY AG(S)
Epstein Barr Virus Early Ag Ab
Epstein-Barr Virus (EBV) Early Antigen
EBVE
CPT Codes
86663
Preferred Specimen
1 mL serum from a gold serum gel tube
Minimum Volume
0.4 mL
Other Acceptable Specimens
Red tube
Instructions
Centrifuge and aliquot serum into a plastic vial.
Transport Container
Plastic vial
Transport Temperature
Refrigerated
Specimen Stability
Refrigerated (preferred): 14 days
Frozen: 14 days
Frozen: 14 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis: Reject
Gross lipemia: Reject
Heat-activated specimen: Reject
Gross lipemia: Reject
Heat-activated specimen: Reject
Methodology
Immunoassay (IA)
FDA Status
Approved
Setup Schedule
Monday through Friday
Report Available
1-3 days
Limitations
Next-generation sequencing may not detect all types of genomic variants. In rare cases, false-negative or false-positive results may occur. The depth of coverage may be variable for some target regions; assay performance below the minimum acceptable criteria or for failed regions will be noted. Given these limitations, negative results do not rule out the diagnosis of a genetic disorder. If a specific clinical disorder is suspected, evaluation by alternative methods can be considered.
There may be regions of genes that cannot be effectively evaluated by sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high guanine-cytosine (GC) content, and repetitive sequences. Confirmation of select reportable variants will be performed by alternate methodologies based on internal laboratory criteria.
This test is validated to detect 95% of deletions up to 75 base pairs (bp) and insertions up to 47 bp. Deletions-insertions (delins) of 40 or more bp, including mobile element insertions, may be less reliably detected than smaller delins.
There may be regions of genes that cannot be effectively evaluated by sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high guanine-cytosine (GC) content, and repetitive sequences. Confirmation of select reportable variants will be performed by alternate methodologies based on internal laboratory criteria.
This test is validated to detect 95% of deletions up to 75 base pairs (bp) and insertions up to 47 bp. Deletions-insertions (delins) of 40 or more bp, including mobile element insertions, may be less reliably detected than smaller delins.
Reference Range
Included with report
Clinical Significance
A third-order test in the diagnosis of infectious mononucleosis, especially in situations when initial testing results (heterophile antibody test) are negative and follow-up testing (viral capsid antigen: VCA IgG, VCA IgM, and Epstein-Barr nuclear antigen) yields inconclusive results.
Aiding in the diagnosis of type 2 or type 3 nasopharyngeal carcinoma (NPC).
This test is not useful for screening patients for NPC.
Aiding in the diagnosis of type 2 or type 3 nasopharyngeal carcinoma (NPC).
This test is not useful for screening patients for NPC.
Performing Laboratory
Mayo Clinic Laboratories, Rochester, Minnesota
Additional Information
Epstein-Barr Virus (EBV), IgG Antibody to Early Antigen, Serum
